Table 1.
Baseline characteristics of patients with HER2-positive metastatic breast cancer
| Characteristic | Pyrotinib plus capecitabine (n = 134) | Lapatinib plus capecitabine (n = 132) |
|---|---|---|
| Median age | 50 years | 49 years |
| ECOG performance status | ||
| 0 | 35% | 33% |
| 1 | 65% | 67% |
| Hormone receptor status | ||
| ER-positive and/or PR-positive | 46% | 44% |
| ER-negative and PR-negative | 54% | 56% |
| Metastatic sites at screening | ||
| Visceral | 77% | 82% |
| Non-visceral | 23% | 18% |
| Previous trastuzumab therapy | ||
| For advanced disease | 59% | 67% |
| As adjuvant or neoadjuvant therapy | 56% | 48% |
| Both | 15% | 15% |
| Median duration of prior trastuzumab for advanced disease | 5.9 months | 4.7 months |
| Resistance to prior trastuzumab | ||
| Yes | 72% | 76% |
| No | 28% | 24% |
| Previous lines of chemotherapy for metastatic disease | ||
| 0 | 43% | 35% |
| 1 | 42% | 49% |
| 2 | 16% | 16% |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PR, progesterone receptor.